Psychiatry
Schizotypal Personality Disorder
4
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Schizotypal Personality Disorder is an early-stage landscape with 4 programs across 2 companies. The most active players are Promius Pharma, LLC, Valeant Pharmaceuticals. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 21
Phase 3
No programs
Approved1
Analysis
Trial Status
5
clinical trials
Unknown status2 · 40%
Completed2 · 40%
Terminated1 · 20%
Clinical Trials
Trial Activity
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
Unknown status·—·Phase 2·NCT01466205·20 enrolled
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Unknown status·—·N/A·NCT00252044
Schizotypal Personality Disorder Risperidone
Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 1/2·NCT02535156·21 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)